Qiagen Claims Market Leadership in HPV Testing as Molecular Dx Business Drives Q2 Revenue Growth | GenomeWeb

By Ben Butkus

Amid reporting a 9 percent spike in second-quarter revenues, Qiagen this week highlighted human papillomavirus testing as a key area of future growth for both its molecular diagnostics and overall business through expected sales of both consumables and instrumentation.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.